TrialBMC cancer2025

Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma.

Yajie Mao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.